HRP20121034T1 - Lijeäśenje upalnih bolesti - Google Patents

Lijeäśenje upalnih bolesti Download PDF

Info

Publication number
HRP20121034T1
HRP20121034T1 HRP20121034TT HRP20121034T HRP20121034T1 HR P20121034 T1 HRP20121034 T1 HR P20121034T1 HR P20121034T T HRP20121034T T HR P20121034TT HR P20121034 T HRP20121034 T HR P20121034T HR P20121034 T1 HRP20121034 T1 HR P20121034T1
Authority
HR
Croatia
Prior art keywords
composition
fty720
chronic inflammatory
subject
treatment
Prior art date
Application number
HRP20121034TT
Other languages
English (en)
Inventor
Betty C. Soliven
Original Assignee
University Of Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Chicago filed Critical University Of Chicago
Publication of HRP20121034T1 publication Critical patent/HRP20121034T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (6)

1. Farmaceutski sastav, naznačen time, da sadrži FTY720, FTY720-P, AAL(R) ili AFD(R) za uporabu u liječenju kronične upalne demijelinacijske polineuropatije (CIDP) kod subjekta.
2. Sastav za uporabu prema zahtjevu 1, naznačen time, da se sastav daje subjektu prije ili poslije nastanka simptoma kronične upalne demijelinacijske polineuropatije. (CIPD).
3. Sastav za uporabu prema zahtjevu 1 ili 2, naznačen time, da je sastav prilagođen za oralno davanje.
4. Sastav za uporabu prema jednom od zahtjeva 1 do 3, naznačen time, da se sastav primjenjuje u kombinaciji s učinkovitom količinom imunosupresanta, kortikosteroida ili imunoglobulina.
5. Farmaceutski sastav koji sadrži FTY720, FTY720-P, AAL(R) ili AFD(R), naznačen time, da se upotrebljava za umanjivanje simptoma kronične upalne demijelinacijske polineuropatije (CIDP) kod subjekta.
6. Farmaceutski sastav koji sadrži FTY720, FTY720-P, AAL(R) ili AFD(R), naznačen time, da se upotrebljava za produljivanje vremena za povratak kronične upalne demijelinacijske polineuropatije (CIDP) kod subjekta.
HRP20121034TT 2006-08-17 2012-12-14 Lijeäśenje upalnih bolesti HRP20121034T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83822206P 2006-08-17 2006-08-17
PCT/US2007/018331 WO2008021532A2 (en) 2006-08-17 2007-08-17 Treatment of inflammatory diseases

Publications (1)

Publication Number Publication Date
HRP20121034T1 true HRP20121034T1 (hr) 2013-01-31

Family

ID=38941849

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20121034TT HRP20121034T1 (hr) 2006-08-17 2012-12-14 Lijeäśenje upalnih bolesti

Country Status (17)

Country Link
US (3) US8258150B2 (hr)
EP (2) EP2392320A1 (hr)
JP (3) JP5216769B2 (hr)
CN (2) CN101553216B (hr)
AU (1) AU2007284337B2 (hr)
BR (1) BRPI0715950A2 (hr)
CA (1) CA2660880C (hr)
DK (1) DK2056807T3 (hr)
ES (1) ES2393631T3 (hr)
HK (1) HK1131047A1 (hr)
HR (1) HRP20121034T1 (hr)
MX (1) MX2009001788A (hr)
PL (1) PL2056807T3 (hr)
PT (1) PT2056807E (hr)
RU (1) RU2440110C2 (hr)
SI (1) SI2056807T1 (hr)
WO (1) WO2008021532A2 (hr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2046315B1 (en) 2006-06-02 2013-04-10 The Ohio State University Research Foundation Therapeutic agents for the treatment of mantle cell lymphoma
JP5216769B2 (ja) * 2006-08-17 2013-06-19 ザ・ユニバーシティ・オブ・シカゴ 炎症性疾患の処置
SI2307007T1 (sl) 2008-07-23 2014-11-28 Novartis Ag Modulatorji sfingozin 1 fosfatnega receptorja in njihova uporaba za zdravljenje mišičnega vnetja
CN102186473B (zh) * 2008-08-18 2014-07-02 诺华股份有限公司 用于治疗周围神经病的化合物
WO2010020609A1 (en) * 2008-08-18 2010-02-25 Novartis Ag Amino alcohol derivatives for the treatment of demyelinating peripheral neuropathies
EP2177521A1 (en) 2008-10-14 2010-04-21 Almirall, S.A. New 2-Amidothiadiazole Derivatives
CN102186845B (zh) 2008-10-17 2016-09-07 阿卡制药有限公司 S1p受体调节剂以及它们的用途
WO2010042998A1 (en) 2008-10-17 2010-04-22 Akaal Pharma Pty Ltd S1p receptors modulators
EP2202232A1 (en) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
EP2210890A1 (en) 2009-01-19 2010-07-28 Almirall, S.A. Oxadiazole derivatives as S1P1 receptor agonists
US8461362B2 (en) 2009-04-13 2013-06-11 The Ohio State University Research Foundation Protein phosphatase 2A-activating agents
CA2759011A1 (en) 2009-04-17 2010-10-21 The Ohio State University Research Foundation Antiadhesion agents
PL3064206T3 (pl) 2009-08-10 2020-02-28 Active Biotech Ab Leczenie choroby Huntingtona z zastosowaniem lakwinimodu
EP2305660A1 (en) 2009-09-25 2011-04-06 Almirall, S.A. New thiadiazole derivatives
EP2343287A1 (en) 2009-12-10 2011-07-13 Almirall, S.A. New 2-aminothiadiazole derivatives
ES2558556T3 (es) * 2010-03-03 2016-02-05 Teva Pharmaceutical Industries Ltd. Tratamiento de nefritis lúpica usando laquinimod
EP2366702A1 (en) 2010-03-18 2011-09-21 Almirall, S.A. New oxadiazole derivatives
EP2390252A1 (en) 2010-05-19 2011-11-30 Almirall, S.A. New pyrazole derivatives
US8309768B2 (en) 2010-11-29 2012-11-13 The Ohio State University Research Foundation FTY720-derived anticancer agents
CN106344576A (zh) * 2011-10-12 2017-01-25 泰华制药工业有限公司 以拉喹莫德和芬戈莫德的组合治疗多发性硬化症
CN104093310A (zh) 2012-02-03 2014-10-08 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
RU2482842C1 (ru) * 2012-04-26 2013-05-27 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения
EP2708898A1 (de) * 2012-09-14 2014-03-19 Sterna Biologicals GmbH & Co. Kg Verfahren zur Diagnose eines molekularen Phänotyps eines an einer mit chronischen Entzündungen einhergehenden Erkrankung leidenden Patienten
EP2916915A4 (en) 2012-11-07 2016-06-22 Teva Pharma LAQUINIMOD AMINE SALTS
MX2015011627A (es) 2013-03-14 2016-05-16 Teva Pharma Cristales de laquinimod sodico y proceso mejorado para la elaboracion de los mismos.
CN103992985A (zh) * 2014-05-09 2014-08-20 上海大学 神经鞘氨醇在中枢神经系统中的作用
CN112237575A (zh) * 2020-11-09 2021-01-19 杭州端丽生物技术有限公司 芬戈莫德在防治鞘脂紊乱引起的神经退行性疾病中的医药用途
CN112924432A (zh) * 2021-04-08 2021-06-08 济宁市第一人民医院 一种血液真菌感染检测试剂盒及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948820A (en) * 1994-08-22 1999-09-07 Yoshitomi Pharmaceutical Industries, Ltd. Benzene compound and pharmaceutical use thereof
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
US6479504B1 (en) * 1999-06-16 2002-11-12 The University Of Iowa Research Foundation Antagonism of immunostimulatory CpG-oligonucleotides by 4-aminoquinolines and other weak bases
RU2478378C2 (ru) * 2002-09-24 2013-04-10 Новартис Аг Органические соединения
CA2539033C (en) * 2003-09-12 2013-03-05 Neuronova Ab Treatment of disease or injury of the nervous system with fty720
JP5216769B2 (ja) * 2006-08-17 2013-06-19 ザ・ユニバーシティ・オブ・シカゴ 炎症性疾患の処置

Also Published As

Publication number Publication date
US20130017190A1 (en) 2013-01-17
US9101576B2 (en) 2015-08-11
WO2008021532A2 (en) 2008-02-21
PL2056807T3 (pl) 2013-02-28
WO2008021532A3 (en) 2008-05-29
CN102526736B (zh) 2016-01-20
AU2007284337B2 (en) 2012-07-19
CA2660880A1 (en) 2008-02-21
JP2015221824A (ja) 2015-12-10
EP2056807A2 (en) 2009-05-13
RU2440110C2 (ru) 2012-01-20
US20150335666A1 (en) 2015-11-26
US20100310547A1 (en) 2010-12-09
CN102526736A (zh) 2012-07-04
HK1131047A1 (en) 2010-01-15
JP2013144694A (ja) 2013-07-25
PT2056807E (pt) 2012-12-21
DK2056807T3 (da) 2012-10-22
SI2056807T1 (sl) 2012-12-31
EP2392320A1 (en) 2011-12-07
US9370497B2 (en) 2016-06-21
CN101553216B (zh) 2012-03-21
CA2660880C (en) 2015-10-13
JP5216769B2 (ja) 2013-06-19
BRPI0715950A2 (pt) 2013-07-30
MX2009001788A (es) 2009-09-23
JP2010500995A (ja) 2010-01-14
US8258150B2 (en) 2012-09-04
EP2056807B1 (en) 2012-09-26
RU2009109418A (ru) 2010-09-27
AU2007284337A1 (en) 2008-02-21
CN101553216A (zh) 2009-10-07
ES2393631T3 (es) 2012-12-26

Similar Documents

Publication Publication Date Title
HRP20121034T1 (hr) Lijeäśenje upalnih bolesti
HRP20211398T1 (hr) Oralne formulacije citidinskih analoga i postupci njihove uporabe
HRP20201243T1 (hr) N-piperidinil acetamidni derivati kao blokatori kalcijevog kanala
HRP20210670T1 (hr) Pripravci za liječenje raka
RS52867B (en) GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS
HRP20110451T1 (hr) Upotreba izotiocijanata kao sredstva protiv mieloma
MX366175B (es) Composiciones fosfolipidicas terapeuticas concentradas.
CL2007002641A1 (es) Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos alergicos, autoinmunes, enfermedades inflamatorias.
BRPI0516238A (pt) composição farmacêutica contendo diclofenaco
WO2007093183A3 (en) Use of a compound that enhances gabaa-ergic neurotransmission for the treatment of inflammatory diseases
EA201690107A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
MX2010002592A (es) Composicion farmaceutica topica para la combinacion de acido fusidico y corticoesteroides.
CL2008000127A1 (es) Compuestos derivados de n-(heteroaril)-1-heteroaril-1h-indol-2-carboxamidas; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor, inflamacion, trastornos urologicos
UY30394A1 (es) Composiciones farmacéuticas estabilizadas que comprenden fesoterodina
WO2008124505A3 (en) Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders
AR094374A1 (es) Composiciones y métodos para el tratamiento de trastornos metabólicos
BRPI0908052A2 (pt) Composições farmacêuticas de entacapone, levodopa e carbidopa com biodisponibilidade melhorada
JP2009520694A5 (hr)
WO2007138466A3 (en) Pharmaceutical compositions comprising meloxicam and tramadol combination
BRPI0508596A (pt) combinação compreendendo ligante alfa-2-delta
BRPI1015539A2 (pt) composições e métodos para tratamento de queimaduras
HRP20210153T1 (hr) Farmaceutski sastavi i uporabe usmjerene prema poremećajima lizosomskog skladištenja
HRP20180468T1 (hr) Novi derivat analoga inzulina
BRPI0908194B8 (pt) Uso de uma anexina a5 recombinante, e stent de eluição de fármaco
HRP20151091T1 (hr) UPORABA 24-norUDCA